Objective-To describe the long term eYcacy and side eVects of the treatment of hemifacial spasm with Dysport and to evaluate two diVerent sites of injection to hopefully reduce side eVects. Methods-This study was designed as a prospective descriptive study. Injections were made subcutaneously around the eye. Peak improvement was subjectively assessed by using a visual analogue scale and reported in percentages (0-100%). Duration of improvement was assessed subjectively and reported in months. Results-Of 175 cases, 17 were lost to follow up and were excluded. 855 treatments were injected in the remaining 158 patients with a median of 4 treatments. The response rate was 97%. Of 855 treatments, the adjusted mean peak and duration of improvement was 77.2 (95% confidence interval (95%CI) 74.7-79.4)% and 3.4 (95%CI 3.2-3.6) months respectively. In 158 patients (complete group), the long term results from the first to the 12th treatment showed that the mean peak improvement ranged from 72.70 to 80.10% and the duration of improvement was 2.60 to 3.71 months. It remained constant throughout (p=0.40, p=0.87 respectively). The most common side eVect was ptosis. Of the 158 patients, 21 completed 12 treatments (subgroup). A separate analysis of this group disclosed a mean peak and duration of improvement from the first to 12th treatments ranging from 70.00 to 78.10% and 2.65 to 4.31 months respectively. Analysis of variance with repeated measures showed no significant variation of peak and duration of improvement over the first to the 12th treatments (p=0.38, p=0.38 respectively). Only 3% of the treatments were unsuccessful but responded to subsequent treatments. The incidence of ptosis was reduced from 27.17% to 9.68% by moving the injection site to the lateral part of orbital orbicularis oculi without any loss of eYcacy. The yearly cost of Dysport is considerably less than Botox. Conclusion-This study is the first to show, in detail, the long term results of treatments of hemifacial spasm with Dysport. The eYcacy is constant throughout the first to 12th treatments in both the complete group and subgroup. Ptosis can be reduced by moving the injection site further up to the lateral part of the orbital orbicularis oculi. The eYcacy of Dysport is comparable with Botox ® in long term follow up. (J Neurol Neurosurg Psychiatry 1998;64:751-757)

Background: Patients with radiation-induced xerostomia produce little or no saliva. Several studies have demonstrated the efficacy of systemic administration of pilocarpine hydrochloride in individuals with post-radiation xerostomia. However, analysis of pilocarpine lozenges for treatment of post-radiation xerostomia in patients with head and neck cancer has not been reported. Methods:The aim of this study was to quantify improvement in clinical symptoms and salivary function after treatment of post-radiation xerostomia with pilocarpine lozenges. In a double-blinded, placebo-controlled trial, 33 head and neck cancer patients were assigned randomly to receive Salagen® tablet, pilocarpine hydrochloride lozenge (3 or 5mg) or placebo lozenge every 10 days. At each visit, a subjective evaluation was undertaken through the use of visual analog scales before and at 180 minutes after treatment. Whole resting saliva was collected before and at 0, 30, 60, 90, 120, 150 and 180 minutes after treatment. Results:The percentage of patients with decreased feeling of oral dryness, sore mouth or speaking difficulties after taking 5-mg pilocarpine lozenge was greater than Salagen® or placebo. There were statistically significant increases in salivary production in pilocarpine treatment groups vs. placebo (P<0.05). Conclusion:The 5-mg pilocarpine lozenge produced the best clinical results, but further investigation with a larger group of patients is required.

No abstract

The accuracy of perinatal and infant mortality rates in most developing countries is questionable. We measured perinatal and infant mortality rates in a rural district of Thailand and compared them with the official statistics to assess accuracy. All births and infant deaths in a rural district of Thailand over a one-year period were surveyed. The corresponding official statistics were also collected. The mothers or the relatives of all stillbirths and infant deaths were interviewed about the registration of the stillbirths or infant deaths. The surveyed perinatal and infant mortality rates were 22.0 and 23.1 respectively. The under-registration of stillbirths was 100% and for infant deaths 45%. All the non-registered infant deaths were in situations in which the infant died before the registration of birth. These results document the degree and nature of under-reporting of perinatal and infant mortality in rural Thailand.